Abbott Laboratories vs. Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
ABT
Abbott Laboratories
$103.69 +0.69%
VS KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares
$78.13 +1.15%
Abbott Laboratories (ABT) comes out ahead, leading on 7 of 9 compared factors.
Size & Scale
| ABT | KNSA | |
|---|---|---|
| Market Cap | $178.19 billion | $6.03 billion |
| Revenue (TTM) | $46.59 billion | $840.85 million |
| Net Income (TTM) | $5.42 billion | $80.66 million |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | KNSA | |
|---|---|---|
| P/E Ratio | 33.56 | 78.92 |
| Price / Book | 3.44 | 9.21 |
| Price / Sales | 3.83 | 7.17 |
ABT leads on 3 of 3 valuation factors.
Profitability
| ABT | KNSA | |
|---|---|---|
| Net Margin | 11.65% | 9.59% |
| Return on Equity | 10.48% | 12.33% |
ABT and KNSA split the profitability factors evenly.
Dividend
| ABT | KNSA | |
|---|---|---|
| Dividend Yield | 2.43% | — |
| Payout Ratio | 81.55 | — |
ABT and KNSA split the dividend factors evenly.
Risk & Sentiment
| ABT | KNSA | |
|---|---|---|
| Short Interest | 0.57% | 0.02% |
KNSA leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, KNSA overview, KNSA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.